Structure–activity studies on different modifications of nociceptin/orphanin FQ: Identification of highly potent agonists and antagonists of its receptor

Meunier, 1995, Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor, Nature, 377, 532, 10.1038/377532a0 Reinscheid, 1995, Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor, Science, 270, 792, 10.1126/science.270.5237.792 Cox, 2000, 321 Chen, 1994, Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family, FEBS Lett, 347, 279, 10.1016/0014-5793(94)00560-5 Mollereau, 1994, ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization, FEBS Lett, 341, 33, 10.1016/0014-5793(94)80235-1 Wang, 1994, cDNA cloning of an orphan opiate receptor gene family member and its splice variant, FEBS Lett, 348, 75, 10.1016/0014-5793(94)00557-5 Calo, 2000, Pharmacology of nociceptin and its receptor: a novel therapeutic target, Br J Pharmacol, 129, 1261, 10.1038/sj.bjp.0703219 Mogil, 2001, The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family, Pharmacol Rev, 53, 381 Guerrini, 2000, Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor, J Med Chem, 43, 2805, 10.1021/jm990075h Calo, 2000, Characterization of [Nphe1]nociceptin(1–13)NH2, a new selective nociceptin receptor antagonist, Br J Pharmacol, 129, 1183, 10.1038/sj.bjp.0703169 Dooley, 1996, Orphanin FQ: receptor binding and analog structure activity relationships in rat brain, Life Sci, 59, L23, 10.1016/0024-3205(96)00261-5 Okada, 2000, Highly potent nociceptin analog containing the Arg–Lys triple repeat, Biochem Biophys Res Commun, 278, 493, 10.1006/bbrc.2000.3822 Rizzi, 2002, [Arg14, Lys15]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies, J Pharmacol Exp Ther, 300, 57, 10.1124/jpet.300.1.57 Guerrini, 2001, Structure–activity studies of the Phe4 residue of nociceptin(1–13)-NH2: identification of highly potent agonists of the nociceptin/orphanin FQ receptor, J Med Chem, 44, 3956, 10.1021/jm010221v Bigoni, 2002, Pharmacological characterisation of [(pX)Phe4]nociceptin(1–13)amide analogues: 1. In vitro studies, Naunyn Schmiedebergs Arch Pharmacol, 365, 442, 10.1007/s00210-002-0548-8 Rizzi, 2002, Pharmacological characterisation of [(pX)Phe4]nociceptin(1–13)amide analogues: 2. In vivo studies, Naunyn Schmiedebergs Arch Pharmacol, 365, 450, 10.1007/s00210-002-0549-7 Zhang, 2002, Novel, potent ORL-1 receptor agonist peptides containing α-helix-promoting conformational constraints, J Med Chem, 45, 5280, 10.1021/jm0202021 Calo, 2002, [Nphe1,Arg14,Lys15] Nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor, Br J Pharmacol, 136, 303, 10.1038/sj.bjp.0704706 Guerrini, 2005, N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands, J Med Chem, 48, 1421, 10.1021/jm040106v Atherton, 1989 Varani, 1998, Nociceptin receptor binding in mouse forebrain membranes: thermodynamic characteristics and structure activity relationships, Br J Pharmacol, 125, 1485, 10.1038/sj.bjp.0702226 Calo, 1998, Structure-activity study of the nociceptin-(1–13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist, J Med Chem, 4, 3360, 10.1021/jm970805q Hughes, 1975, Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antagonist potencies of narcotic analgesics, Br J Pharmacol, 53, 371, 10.1111/j.1476-5381.1975.tb07373.x Jenkinson, 1995, International Union of Pharmacology Committee on receptor nomenclature and drug classification: XI. Recommendations on terms and symbols in quantitative pharmacology, Pharmacol Rev, 47, 255 Hruby, 2002, Designing peptide receptor agonists and antagonists, Nat Rev Drug Discov, 1, 847, 10.1038/nrd939 Schwyzer, 1977, ACTH: a short introductory review, Ann N Y Acad Sci, 297, 3, 10.1111/j.1749-6632.1977.tb41843.x Cowell, 2002, Design and synthesis of peptide antagonists and inverse agonists for G protein-coupled receptors, Methods Enzymol, 343, 49, 10.1016/S0076-6879(02)43127-8 Guerrini, 1997, Address and message sequences for the nociceptin receptor: a structure–activity study of nociceptin-(1–13)-peptide amide, J Med Chem, 40, 1789, 10.1021/jm970011b Klaudel, 2004, Solution conformational study of nociceptin and its 1–13 and 1–11 fragments using circular dichroism and two-dimensional NMR in conjunction with theoretical conformational analysis, J Pept Sci, 10, 678, 10.1002/psc.576 Orsini, 2005, The nociceptin pharmacophore site for opioid receptor binding derived from the NMR structure and bioactivity relationships, J Biol Chem, 280, 8134, 10.1074/jbc.M406405200 Salvadori, 1999, Structure activity studies on nociceptin/orphanin FQ: from full agonist, to partial agonist, to pure antagonist, Il Famaco, 54, 810, 10.1016/S0014-827X(99)00108-1 Carra, 2005, [(pF)Phe4,Arg14, Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor, J Pharmacol Exp Ther, 312, 1114, 10.1124/jpet.104.077339 Reinscheid, 1996, Structure–activity relationship studies on the novel neuropeptide orphanin FQ, J Biol Chem, 271, 14163, 10.1074/jbc.271.24.14163 Chen, 2003, Design and parallel synthesis of piperidine libraries targeting the nociceptin (N/OFQ) receptor, Bioorg Med Chem Lett, 19, 3247, 10.1016/S0960-894X(03)00665-6 Guerrini, 2004, Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity, J Pept Res, 63, 477, 10.1111/j.1399-3011.2004.00157.x Topham, 1998, Molecular modeling of the ORL1 receptor and its complex with nociceptin, Protein Eng, 11, 1163, 10.1093/protein/11.12.1163 Mouledous, 2000, Functional inactivation of the nociceptin receptor by alanine substitution of glutamine 286 at the C terminus of transmembrane segment VI: evidence from a site-directed mutagenesis study of the ORL1 receptor transmembrane-binding domain, Mol Pharmacol, 57, 495, 10.1124/mol.57.3.495 Pogozheva, 1998, Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints, Biophys J, 75, 612, 10.1016/S0006-3495(98)77552-6